Impact of COVID-19 Pandemic on Treatment Management and Clinical Outcome of Aneurysmal Subarachnoid Hemorrhage - A Single-Center Experience.
COVID-19
aneurysmal subarachnoid hemorrhage (aSAH)
cerebral vasospasm (CVS)
clinical outcome
delayed cerebral ischemia (DCI)
healthcare system
pandemic
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2022
2022
Historique:
received:
15
12
2021
accepted:
17
02
2022
entrez:
7
4
2022
pubmed:
8
4
2022
medline:
8
4
2022
Statut:
epublish
Résumé
Previous studies reported decreased volumes of acute stroke admissions during the COVID-19 pandemic. We aimed to examine whether aneurysmal subarachnoid hemorrhage (aSAH) volumes demonstrated similar declines in our department. Furthermore, the impact of the pandemic on disease progression should be analyzed. We conducted a retrospective study in the neurosurgical department of the university hospital Frankfurt including patients with the diagnosis of aSAH during the first year of the COVID pandemic. One year cumulative volume for aSAH hospitalization procedures was compared to the year before (03/2020 - 02/2021 vs. 03/2019 - 02/2020) and the last 5 pre-COVID-pandemic years (2015-2020). All relevant patient characteristics concerning family history, disease history, clinical condition at admission, active/past COVID-infection, treatment management, complications, and outcome were analyzed. Compared to the 84 hospital admissions during the pre-pandemic years, the number of aSAH hospitalizations ( There was a relative decrease in the number of patients with aSAH during the COVID-19 pandemic. Despite the extremely different conditions of hospitalization, there was no impairing significant effect on the treatment and outcome of admitted patients with aSAH. A past COVID infection seemed to be an irrelevant limiting factor concerning favorable outcomes.
Sections du résumé
Background
UNASSIGNED
Previous studies reported decreased volumes of acute stroke admissions during the COVID-19 pandemic. We aimed to examine whether aneurysmal subarachnoid hemorrhage (aSAH) volumes demonstrated similar declines in our department. Furthermore, the impact of the pandemic on disease progression should be analyzed.
Methods
UNASSIGNED
We conducted a retrospective study in the neurosurgical department of the university hospital Frankfurt including patients with the diagnosis of aSAH during the first year of the COVID pandemic. One year cumulative volume for aSAH hospitalization procedures was compared to the year before (03/2020 - 02/2021 vs. 03/2019 - 02/2020) and the last 5 pre-COVID-pandemic years (2015-2020). All relevant patient characteristics concerning family history, disease history, clinical condition at admission, active/past COVID-infection, treatment management, complications, and outcome were analyzed.
Results
UNASSIGNED
Compared to the 84 hospital admissions during the pre-pandemic years, the number of aSAH hospitalizations (
Conclusion
UNASSIGNED
There was a relative decrease in the number of patients with aSAH during the COVID-19 pandemic. Despite the extremely different conditions of hospitalization, there was no impairing significant effect on the treatment and outcome of admitted patients with aSAH. A past COVID infection seemed to be an irrelevant limiting factor concerning favorable outcomes.
Identifiants
pubmed: 35386414
doi: 10.3389/fneur.2022.836422
pmc: PMC8978712
doi:
Types de publication
Journal Article
Langues
eng
Pagination
836422Informations de copyright
Copyright © 2022 Kashefiolasl, Qasem, Brawanski, Funke, Keil, Hattingen, Foerch, Seifert, Prinz, Czabanka and Konczalla.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Stroke. 2020 Jun;51(6):1896-1901
pubmed: 32347790
J Clin Nurs. 2018 Mar;27(5-6):e1068-e1077
pubmed: 29076614
J Neurosurg. 2017 Feb;126(2):518-526
pubmed: 27058204
Anesth Analg. 2020 Jul;131(1):55-60
pubmed: 32221172
Stroke. 2020 Jul;51(7):2224-2227
pubmed: 32516064
Neurosurgery. 2021 Feb 16;88(3):674-685
pubmed: 33269399
J Neurosurg Sci. 2020 Aug;64(4):409-410
pubmed: 32347681
Circ Cardiovasc Qual Outcomes. 2020 Apr;13(4):e006631
pubmed: 32182131
Nat Med. 2020 Jun;26(6):842-844
pubmed: 32398875
World Neurosurg. 2020 Jul;139:744-745
pubmed: 32474100
Eur J Anaesthesiol. 2015 Mar;32(3):168-76
pubmed: 25303971
N Engl J Med. 2020 May 21;382(21):2049-2055
pubmed: 32202722
Stroke. 2011 Nov;42(11):3258-64
pubmed: 21921276
Stroke Vasc Neurol. 2021 Dec;6(4):542-552
pubmed: 33771936
J Stroke Cerebrovasc Dis. 2013 Jan;22(1):22-7
pubmed: 21719308
Acta Neurochir (Wien). 2020 Jun;162(6):1229-1240
pubmed: 32314059
Stroke. 2020 Sep;51(9):2664-2673
pubmed: 32755347
Nat Rev Immunol. 2020 Jul;20(7):448
pubmed: 32488203
Neurol Med Chir (Tokyo). 2019 Apr 15;59(4):126-132
pubmed: 30867357
Data Brief. 2021 Dec;39:107480
pubmed: 34664028
Acta Neurochir (Wien). 2020 Aug;162(8):1795-1801
pubmed: 32514620
World Neurosurg. 2020 Jul;139:e877-e884
pubmed: 32461176
J Neurointerv Surg. 2020 Jul;12(7):639-642
pubmed: 32467244
J Stroke Cerebrovasc Dis. 2020 Sep;29(9):105010
pubmed: 32807425
N Engl J Med. 2020 May 14;382(20):e60
pubmed: 32343504